STOCK TITAN

Allarity Therapeutics Granted U.S. Patent for Stenoparib’s Clinical Dosing Regimen, with Protection Into 2045

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Allarity Therapeutics (ALLR) received a U.S. patent covering stenoparib treatment regimens, with protection for the claimed methods extending into 2045. The patent's 36 allowed claims cover twice-daily oral dosing at specified doses and schedules, including treatment methods for advanced ovarian cancer and other solid tumors. The claims also cover patients whose disease did not respond to prior therapies, including other PARP inhibitors.

The patent complements Allarity's existing U.S. patent for a stenoparib-specific test designed to identify patients more likely to benefit. Allarity plans to advance the twice-daily regimen to pivotal trials, which are intended to support a regulatory decision. The ongoing Phase 2 ovarian cancer study added two patient groups for separate evaluation. A separate Phase 2 trial is enrolling patients with relapsed small cell lung cancer to study stenoparib with temozolomide.

Loading...
Loading translation...
7 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointU.S. dosing patent protects the claimed stenoparib treatment methods into 2045, with 36 allowed claims.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Pivotal trial plans call for advancing the twice-daily stenoparib regimen.
  • Minor pointTwice-daily oral dosing claims cover specified doses and schedules for advanced ovarian cancer and other solid tumors.
  • Minor pointPrior-treatment coverage includes patients whose disease did not respond to earlier therapies, including other PARP inhibitors.
  • Minor pointPhase 2 ovarian cancer protocol added two patient groups for evaluation separately from the initial group.
2 minor points
  • Minor pointEarlier Phase 2 protocol showed durable clinical benefit, Allarity reported, in twice-daily recipients with two or more prior lines of therapy.
  • Minor pointPhase 2 lung cancer combination trial is enrolling patients with relapsed small cell lung cancer at multiple U.S. Veterans Affairs sites.

Negative

  • Minor point. Forward-looking: it has not happened yet and may not happen.Earlier Phase 2 ovarian cancer analyses remain subject to change as the study data mature.

Key Figures

Allowed claims: 36 allowed claims Patent protection: Into 2045
Allowed claims
36 allowed claims
U.S. patent covering stenoparib treatment regimens
Patent protection
Into 2045
Claimed stenoparib treatment methods

Historical Context

2 past events · Latest: Nov 16
2 events
  1. Nov 16

    Phase 2 expansion

    24h Move
    -8.2%

    Expanded the ovarian cancer trial cohorts and reported earlier clinical signals with twice-daily stenoparib.

  2. Sep 30

    DRP update

    24h Move
    +8.8%

    Higher pretreatment DRP scores were associated with longer overall survival in an earlier Phase 2 cohort.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

parp inhibitor, recist, companion diagnostic
3 terms
parp inhibitor medical
"including other PARP inhibitors"
A PARP inhibitor is a type of drug that blocks a protein cells use to repair damaged DNA, making it harder for cancer cells to survive and multiply. For investors, these drugs matter because regulatory approvals, trial results, patent status, and competition directly affect potential sales, company valuations and partnership opportunities — think of a PARP inhibitor as a targeted tool that can make existing cancer treatments more effective and create commercial value if proven safe and effective.
recist medical
"under standard Response Evaluation Criteria in Solid Tumors (“RECIST”)"
RECIST (Response Evaluation Criteria In Solid Tumors) is a standardized set of rules doctors and researchers use to measure how solid tumors change over time on medical scans, categorizing whether a tumor shrinks, grows, or stays the same. Investors pay attention because RECIST-based results often serve as clear, comparable trial endpoints that influence drug approvals, market expectations and company valuations—like using a reliable ruler to track progress in a development program.
companion diagnostic medical
"stenoparib-specific Drug Response Predictor (DRP®) companion diagnostic"
A companion diagnostic is a medical test designed to identify which patients are likely to benefit from a specific drug or medical treatment, much like a key that shows whether a particular lock will open. For investors, these tests matter because they can increase a drug’s chances of approval and market uptake, create a separate revenue stream, and reduce commercial risk by matching treatments to the patients most likely to respond.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google


Patent with 36 allowed claims covering twice-daily treatment in ovarian cancer and other solid tumors

Strengthens intellectual property supporting the dosing strategy used in the Company's ongoing Phase 2 program


TARPON SPRINGS, Fla., November 18, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that the United States Patent and Trademark Office (“USPTO”) has granted a U.S. patent covering stenoparib treatment regimens. The patent is to provide protection for the claimed methods into 2045.

The 36 allowed claims cover twice-daily oral administration of stenoparib, including specified dose levels and treatment schedules relevant to Allarity's clinical development program. They also encompass methods of treating advanced ovarian cancer and other solid tumors, including breast, colon, pancreatic and prostate cancers, as well as patients whose disease has not responded to prior therapies, including other PARP inhibitors.

“The commercial significance of this patent is enormous. Its coverage of our twice-daily dosing strategy is critical as this is the dosing regimen we intend to advance to pivotal trials,” said Thomas Jensen, Chief Executive Officer of Allarity Therapeutics. “A protection period extending into 2045 strengthens the foundation for continued investment in stenoparib and fuels future partnering discussions as we generate the clinical data needed to support FDA approval”.

The patent complements Allarity's previously issued U.S. patent covering its stenoparib-specific Drug Response Predictor (DRP®) companion diagnostic. Together, these patents enable the Company's strategy to develop stenoparib alongside a proprietary approach to identifying patients most likely to benefit.

The patent, titled Methods for Treating Cancer, has been assigned U.S. Patent No. 12,806,205 and arises from U.S. Patent Application No. 18/606,590.

About Allarity Therapeutics

Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage pharmaceutical company focused on developing personalized cancer treatments. The Company is developing stenoparib, a novel PARP/tankyrase inhibitor for patients with advanced ovarian cancer, and is using its proprietary DRP® technology to develop a companion diagnostic designed to identify patients expected to derive the greatest clinical benefit from stenoparib. Allarity’s principal operations are located in Denmark, and its U.S. business address is in Florida. For more information, visit www.allarity.com.

About Stenoparib/2X-121

Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. Tankyrases have emerged as potential therapeutic targets in cancer due in part to their role in regulating the WNT signaling pathway. Aberrant WNT/β-catenin signaling has been implicated in the development and progression of numerous cancers, including drug-resistant cancers. Through its inhibition of PARP and the WNT signaling pathway, stenoparib has the potential to provide therapeutic benefit across multiple cancer types, including ovarian cancer, small cell lung cancer and colorectal cancer.

Allarity has secured exclusive global rights to develop and commercialize stenoparib, which was originally developed by Eisai Co., Ltd. and was formerly known as E7449 and 2X-121.
Under an earlier Phase 2 protocol evaluating stenoparib in patients with advanced ovarian cancer, Allarity observed promising and durable clinical benefit in patients who received two or more prior lines of therapy and were treated with stenoparib twice daily. Updated data from this earlier protocol were presented at the AACR Special Conference on Advances in Ovarian Cancer in September 2025. These analyses remain subject to change as the study data mature.

Based on the emerging clinical experience with stenoparib, Allarity developed a new protocol that began enrolling patients with platinum-resistant or platinum-ineligible ovarian cancer in the summer of 2025. Allarity has amended the protocol to add two patient groups that will be evaluated separately from the initial cohort enrolled under that protocol, namely patients with primary platinum-refractory disease and patients whose disease can be evaluated clinically but is not measurable under standard Response Evaluation Criteria in Solid Tumors (“RECIST”). The study is designed to advance the clinical development of stenoparib toward potential FDA approval.
In parallel, a separate Phase 2 trial evaluating stenoparib in combination with temozolomide for patients with relapsed small cell lung cancer, or SCLC, began enrolling in early 2026 and is currently enrolling patients at multiple U.S. Department of Veterans Affairs sites.

About the Drug Response Predictor – DRP® Companion Diagnostic

Allarity uses its drug-specific DRP® technology to identify patients who, based on the gene expression signature of their cancer, may be more likely to benefit from a particular drug. By screening patients before treatment and selecting those with a sufficiently high, drug-specific DRP score, the DRP technology is designed to increase the likelihood of therapeutic benefit.

The DRP methodology is based on comparisons of sensitive and resistant human cancer cell lines and incorporates transcriptomic data, clinical tumor biology filters and prior clinical trial outcomes. The DRP uses messenger RNA expression profiles derived from patient biopsies to generate drug-specific predictive scores.

The DRP® platform has demonstrated the ability to provide statistically significant predictions of clinical outcome following drug treatment across dozens of retrospective and prospective clinical studies. The platform is designed for potential application across multiple cancer types, is patented for dozens of anti-cancer drugs and has been extensively described in peer-reviewed scientific literature.

Follow Allarity on Social Media
LinkedIn: https://www.linkedin.com/company/allaritytx/

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable federal securities laws. Forward-looking statements reflect current expectations or forecasts regarding future events. The words “anticipates,” “believes,” “continues,” “could,” “estimates,” “expects,” “intends,” “may,” “might,” “plans,” “possible,” “potential,” “predicts,” “projects,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding the scheduled issuance on November 24, 2026, the expected patent term extending into 2045, and the scope, validity, enforceability and commercial value of U.S. Patent No. 12,806,205; the ability of the patent claims to protect methods of treating cancer with stenoparib, including dosing regimens relevant to advanced ovarian cancer; the anticipated contribution of the patent to the Company’s intellectual property and commercial strategy; and the Company’s plans and ability to advance stenoparib toward late-stage development, regulatory approval and commercialization. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the patent issuance process, including potential delays or changes before grant; the scope, validity, enforceability, maintenance and interpretation of the patent; potential third-party challenges or other actions affecting the Company’s intellectual property rights; the Company’s ability to obtain, maintain and enforce intellectual property protection; the ability of stenoparib to demonstrate sufficient safety, efficacy, tolerability or clinical benefit to support further development or regulatory approval; the Company’s ability to conduct, enroll and complete ongoing and future clinical trials; the possibility that prior clinical observations may not be confirmed in ongoing or future studies; and the Company’s ability to secure sufficient financial, operational, manufacturing and clinical resources to continue development of stenoparib. For a discussion of risks and uncertainties and other important factors that could cause actual results to differ materially from those contained in the forward-looking statements, see the risk factors and other disclosures in Allarity’s filings with the SEC, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. These filings are available through the SEC’s website. All information in this press release is as of the date of the release, and the Company undertakes no obligation to update or revise this information, except as required by applicable law.

###

Company Contact:
         investorrelations@allarity.com

Media Contact:
     Thomas Pedersen
     Carrotize PR & Communications
     +45 6062 9390
     tsp@carrotize.com 
        

Attachment


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Allarity Therapeutics' U.S. stenoparib patent cover, and how long does protection last?

U.S. Patent No. 12,806,205 protects claimed stenoparib treatment methods into 2045. Its 36 allowed claims cover specified twice-daily oral regimens and treatment methods for advanced ovarian cancer and other solid tumors, including breast, colon, pancreatic and prostate cancers.

Which patient groups did Allarity Therapeutics add to its Phase 2 stenoparib ovarian cancer study?

Allarity added patients with primary platinum-refractory disease, meaning the disease did not respond to initial platinum treatment, and patients whose disease can be evaluated clinically but cannot be measured under standard tumor response criteria. Both groups will be evaluated separately from the initial group.

Keep reading